Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …

Pancreatic ductal adenocarcinoma (PDA) has become one of the leading causes of cancer-
related deaths across the world. A lack of durable responses to standard-of-care …

Pancreatic cancer is a highly lethal disease, for which mortality closely parallels incidence.
Most patients with pancreatic cancer remain asymptomatic until the disease reaches an …

INTRODUCTION Pancreatic ductal adenocarcinoma (PDA) is the fourth most common
cause of death from cancer worldwide and has a 5-year survival rate of 6%. Patients who …

The dismal prognosis of pancreatic adenocarcinoma is due in part to a lack of molecular
information regarding disease development. Established cell lines remain a useful tool for …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the
United States with a median survival of< 6 mo and a dismal 5-yr survival rate of 3%–5%. The …

Pancreatic cancers arise predominantly from ductal epithelial cells of the exocrine pancreas
and are of the ductal adenocarcinoma histological subtype (PDAC). PDAC is an aggressive …

TP53 mutation occurs in 50–75% of human pancreatic ductal adenocarcinomas (PDAC)
following an initiating activating mutation in the KRAS gene. These p53 mutations frequently …

Pancreatic ductal adenocarcinoma (PDAC) is characterized by near-universal mutations in
KRAS and frequent deregulation of crucial embryonic signalling pathways, including the …

Invasive pancreatic ductal adenocarcinoma is an almost uniformly fatal disease. Several
distinct noninvasive precursor lesions can give rise to invasive adenocarcinoma of the …